Dialyse- und Ultrafiltrationsverfahren bei kardio-renalem Syndrom. Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. und der Deutschen Gesellschaft für Nephrologie e.V.^[*]

 

 Buy Article Permissions and Reprints

This paper is dedicated to our colleague and coauthor Prof. Dr. Bernd Krumme (4. Sept. 1961 - 7. Sept. 2013)

Zusammenfassung

Patienten mit fortgeschrittener Herzinsuffizienz weisen oftmals auch eine begleitende Niereninsuffizienz auf. Diese enge pathophysiologische Interaktion wird als kardio-renales Syndrom (KRS) bezeichnet. Die hydropische Dekompensation ist bei diesen Patienten einer der häufigsten Hospitalisierungsgründe. Wenn trotz Optimierung der Therapie eine hydropische Dekompensation bzw. eine Diuretikaresistenz eintritt, kann eine Ultrafiltrationstherapie notwendig sein. In der akuten Dekompensation wird bei den oftmals intensivstationspflichtigen Patienten eine extrakorporale Nierenersatztherapie bevorzugt durchgeführt. Bei der chronischen Dekompensation, insbesondere wenn diese mit Aszitesbildung einhergeht, bietet eine peritoneale Ultrafiltration verfahrensspezifische Vorteile. Eine enge Kooperation zwischen Intensivmedizinern, Kardiologen und Nephrologen ist Voraussetzung für die optimale Behandlung des Patienten mit KRS.

Abstract

Renal failure is common in patients with severe heart failure. This complex pathophysiological interaction has been classified as cardio-renal syndrome. In these patients hydropic decompensation is the main cause of hospitalization. In patients with refractory heart failure, characterized by diuretic resistance and congestion due to volume overload, ultrafiltration has to be considered. In acute decompensated heart failure with worsening of renal function, extracorporeal ultrafiltration is the preferred treatment modality. On the other hand, patients suffering from chronic decompensated heart failure, particularly patients with ascites, will profit from the treatment specific advantages of peritoneal ultrafiltration. Prerequisite for an optimized care of patients with cardio-renal syndrome is the close collaboration among intensive care doctors, cardiologists and nephrologists.

*Dieser Artikel wurde in den Zeitschriften „Der Kardiologe“ (DOI: 10.1007/s12181-013-0549-5) und „Deutsche Medizinische Wochenschrift DMW“ (DOI: 10.1055/s-0033-1360037) zeitgleich publiziert.

• Literatur

• 1 McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur Heart J 2012; 33: 1787-1847
  CrossrefPubMedGoogle Scholar
• 2 Anavekar NS, McMurray JJV, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295
  CrossrefPubMedGoogle Scholar
• 3 Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210
  CrossrefPubMedGoogle Scholar
• 4 Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018
  CrossrefPubMedGoogle Scholar
• 5 Luthi JC, Flanders WD, Burnier M et al. Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients. BMC nephrology 2006; 7: 3
  CrossrefPubMedGoogle Scholar
• 6 McAlister FA, Ezekowitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009
  CrossrefPubMedGoogle Scholar
• 7 Ronco C, McCullough P, Anker SD et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31: 703-711
  CrossrefPubMedGoogle Scholar
• 8 Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012; 60: 1031-1042
  CrossrefPubMedGoogle Scholar
• 9 Shamseddin MK, Parfrey PS. Mechanisms of the cardiorenal syndromes. Nature reviews. Nephrology 2009; 5: 641-649
  PubMedGoogle Scholar
• 10 Sheppard R, Panyon J, Pohwani AL et al. Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail 2004; 10: 380-383
  CrossrefPubMedGoogle Scholar
• 11 Dini FL, Demmer RT, Simioniuc A et al. Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure. Eur J Heart Fail 2012; 14: 287-294
  CrossrefPubMedGoogle Scholar
• 12 Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589-596
  CrossrefPubMedGoogle Scholar
• 13 Testani JM, Khera AV, St John Sutton MG et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; 105: 511-516
  CrossrefPubMedGoogle Scholar
• 14 Dikow R, Kihm LP, Zeier M et al. Increased infarct size in uremic rats: reduced ischemia tolerance?. J Am Soc Nephrol 2004; 15: 1530-1536
  CrossrefPubMedGoogle Scholar
• 15 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl. 01) S1-S266
  PubMedGoogle Scholar
• 16 Swedberg K, Eneroth P, Kjekshus J et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990; 66: 40D-45D
  CrossrefPubMedGoogle Scholar
• 17 Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
  CrossrefPubMedGoogle Scholar
• 18 Vardeny O, Wu DH, Desai A et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012; 60: 2082-2089
  CrossrefPubMedGoogle Scholar
• 19 Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805
  CrossrefPubMedGoogle Scholar
• 20 O’Connor CM, Abraham WT, Albert NM et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662-673
  CrossrefPubMedGoogle Scholar
• 21 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) et al. Nationale Versorgungsleitlinie Herzinsuffizienz. http://www.herzinsuffizienz.versorgungsleitlinien.de/
  Google Scholar
• 22 Chertow GM, Normand SLT, McNeil BJ. Renalism: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 2004; 15: 2462-2468
  CrossrefPubMedGoogle Scholar
• 23 Feenstra J, Heerdink ER, Grobbee DE et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002; 162: 265-270
  CrossrefPubMedGoogle Scholar
• 24 Flather MD, Yusuf S, Køber L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581
  CrossrefPubMedGoogle Scholar
• 25 Westenfeld R, Rump LC. Kontrastmittelinduzierte Nephropathie. Dtsch Med Wochenschr 2013; 138: 715-718
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Elahi M, Asopa S, Pflueger A et al. Acute kidney injury following cardiac surgery: impact of early versus late haemofiltration on morbidity and mortality. Eur J Cardiothorac Surg 2009; 35: 854-863
  CrossrefPubMedGoogle Scholar
• 27 Payen D, de Pont AC, Sakr Y et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Critical care 2008; 12: R74
  CrossrefPubMedGoogle Scholar
• 28 Udani SM, Murray PT. The use of renal replacement therapy in acute decompensated heart failure. Semin Dial 2009; 22: 173-179
  CrossrefPubMedGoogle Scholar
• 29 Rubinger D, Backenroth R, Sapoznikov D. Sympathetic activation and baroreflex function during intradialytic hypertensive episodes. PloS one 2012; 7: e36943
  CrossrefPubMedGoogle Scholar
• 30 Marenzi G, Lauri G, Grazi M et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001; 38: 963-968
  CrossrefPubMedGoogle Scholar
• 31 Bart BA, Boyle A, Bank AJ et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005; 46: 2043-2046
  CrossrefPubMedGoogle Scholar
• 32 Jaski BE, Ha J, Denys BG et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003; 9: 227-231
  CrossrefPubMedGoogle Scholar
• 33 Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683
  CrossrefPubMedGoogle Scholar
• 34 Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304
  CrossrefPubMedGoogle Scholar
• 35 Testani JM, Brisco MA, Chen J et al. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 2013; 62: 516-524
  CrossrefPubMedGoogle Scholar
• 36 Testani JM, Chen J, McCauley BD et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265-272
  CrossrefPubMedGoogle Scholar
• 37 Jefferies HJ, Virk B, Schiller B et al. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011; 6: 1326-1332
  CrossrefPubMedGoogle Scholar
• 38 Selby NM, McIntyre CW. Peritoneal dialysis is not associated with myocardial stunning. Perit Dial Int 2011; 31: 27-33
  CrossrefPubMedGoogle Scholar
• 39 Nakhoul F, Yigla M, Gilman R et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20: 1686-1692
  CrossrefPubMedGoogle Scholar
• 40 Ori Y, Korzets A, Katz M et al. Haemodialysis arteriovenous access--a prospective haemodynamic evaluation. Nephrol Dial Transplant 1996; 11: 94-97
  CrossrefPubMedGoogle Scholar
• 41 Yigla M, Nakhoul F, Sabag A et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123: 1577-1582
  CrossrefPubMedGoogle Scholar
• 42 Cnossen TT, Kooman JP, Krepel HP. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant 2012; 27: 2794-2799
  CrossrefPubMedGoogle Scholar
• 43 Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564
  PubMedGoogle Scholar
• 44 Menon MK, Naimark DM, Bargman JM et al. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-2213
  CrossrefPubMedGoogle Scholar
• 45 Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2. Am J Kidney Dis 2003; 41: 1293-1302
  CrossrefPubMedGoogle Scholar
• 46 Wang AYM, Wang M, Woo J et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 2186-2194
  CrossrefPubMedGoogle Scholar
• 47 Cnossen TT, Kooman JP, Konings CJAM et al. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood purification 2010; 30146-152
  PubMedGoogle Scholar
• 48 Nakayama M, Nakano H, Nakayama M. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol 2010; 55: 49-54
  CrossrefPubMedGoogle Scholar
• 49 Ryckelynck JP, Lobbedez T, Valette B et al. Peritoneal ultrafiltration and treatment-resistant heart failure. Nehrol Dial Transplant 1998; 13 (Suppl. 04) 56-59
  PubMedGoogle Scholar
• 50 Sánchez JE, Ortega T, Rodríguez C et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nehrol Dial Transplant 2010; 25: 605-610
  PubMedGoogle Scholar
• 51 Koch M, Haastert B, Kohnle M et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 2012; 14: 530-539
  CrossrefPubMedGoogle Scholar
• 52 Polkinghorne KR, Chin GK, Macginley RJ et al. KHA-CARI guideline: Vascular access – central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology (Carlton, Vic.) 2013; doi: DOI: 10.1111/nep.12132. [Epub ahead of print]
  PubMedGoogle Scholar